fda

Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment Technology

Source Node:
Time Stamp: April 15, 2024 1:26 PM - Modified On: April 15, 2024 - Published By:
Source Cluster:
Republished By Plato

  Company is targeting pancreatic cancer pain with advanced nerve detection and treatment technology New York, March 12, 2024 - (Plato Data) - Benzinga has published a new article on Autonomix Medical Inc. (NASDAQ: AMIX), featuring the company's groundbreaking approach to peripheral nervous system (PNS) disorders. The Benzinga article delves into the critical role of the PNS in human health and highlights how Autonomix Medical is pioneering with its catheter-based microchip sensing array technology. The article provides a comprehensive look at how Autonomix Medical is redefining treatment protocols for nerve-related

Lindsay Rosenwald’s Fortress Bio (NASDAQ: FBIO) Spotlight on 2024 Milestones from Subsidiaries

Source Node:
Time Stamp: February 2, 2024 2:30 PM - Modified On: February 2, 2024 - Published By:
Source Cluster:
Republished By Plato

  New York, Feb 2, 2024 - (Plato Data)- Fortress Biotech (Fortress Bio), a unique biotech company led by industry veteran Dr. Lindsay Rosenwald, focused on identifying, in-licensing and developing high-potential marketed drugs and development-stage drug candidates in-house and through its subsidiary partner companies, has announced multiple new milestones to start 2024 with a bang. Avenue Therapeutics Finalizes Phase 3 Study for IV Tramadol with FDA Avenue Therapeutics, a subsidiary of Fortress Bio, has reached a significant milestone in its quest to introduce new therapies for neurologic diseases. The company

Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate

Source Node:
Time Stamp: January 29, 2024 6:55 AM - Modified On: January 29, 2024 - Published By:
Source Cluster:
Republished By Plato

New York, Jan. 29, 2024 - (Plato Data) - Corbus Pharmaceuticals (NASDAQ:CRBP) jumped on Friday after announcing positive data from a small group of cancer patients who received its antibody-drug conjugate (ADC) CRB-701 in a Phase 1 trial. Citing a December data cut in patients with cancers expressing a tumor-associated antigen called nectin-4, Corbus (CRBP) said that CRB-701 led to an objective response rate (ORR) of 43%, including three partial responses. The data from the first eighteen participants who received the first six dose levels represented the readout, which was

NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.

Source Node:
Time Stamp: October 24, 2023 11:55 AM - Modified On: October 24, 2023 - Published By:
Source Cluster:
Republished By Plato

Summary: Progress in Neurodegenerative Research:  NKGen’s Phase 1/2a Clinical Trial for SNK01 on Track for End-of-Year Initiation SANTA ANA, Calif., Oct. 24, 2023 (Plato / Amplifi) -- Today, NKGen Biotech Inc. (Nasdaq: NKGN), a trailblazer in the field of autologous, allogeneic, and CAR-NK natural killer cell therapeutics, proudly announced the progression of its SNK01 program targeting Alzheimer’s Disease (AD), backed by the green light from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application. NKGen is gearing up to initiate its Phase 1/2a clinical trial

Erez Capital Announces Additional Venture Partners

Source Node:
Time Stamp: August 4, 2023 6:52 AM - Modified On: August 4, 2023 - Published By:
Source Cluster:
Republished By Plato

Erez Capital, a emerging venture capital fund investing in disruptive technologies, is thrilled to announce the addition of new Venture Partners. Boston, Massachusetts, United States - August 3rd, 2023 — Erez Capital, a emerging venture capital fund investing in disruptive technologies, is thrilled to announce its addition of 40 Venture Partners to join the fund. These new partners will play an important role in the quickly developing artificial intelligence ecosystem - specifically in the proptech, medtech and fintech sectors. “This fund and its investments will represent the consensus of experts,

Renowned Physician-Pharmacist Dr. Anita Gupta joins Erez Capital, Bringing Healthcare Innovation Expertise on Board.

Source Node:
Time Stamp: July 26, 2023 2:17 PM - Modified On: July 26, 2023 - Published By:
Source Cluster:
Republished By Plato

Boston, MA, July 26th, 2023-- Erez Capital is proud to announce the addition of Dr. Anita Gupta to its esteemed team of Venture Partners. Dr. Gupta, a global leader in healthcare innovation, is renowned for her ground-breaking contributions to the medical field and her exceptional expertise in anesthesiology and pain management. With an illustrious career and a portfolio of remarkable accomplishments, Dr. Anita Gupta has made a significant impact on healthcare innovation and patient advocacy. As a World Economic Forum Member Expert, she has been recognized as one of the

Sacrix LLC To Be Issued A 3D Porous Patent On Its Threaded Implant And Lateral-Oblique Sacroiliac Joint Fusion Technique On September 28th, 2021

Source Node: https://www.prweb.com/releases/sacrix_llc_to_be_issued_a_3d_porous_patent_on_its_threaded_implant_and_lateral_oblique_sacroiliac_joint_fusion_technique_on_september_28th_2021/prweb18205376.htm
Time Stamp: September 18, 2021 9:00 PM - Modified On: September 18, 2021 - Published By:
Source Cluster:
Republished By Plato

Sacrix New 3D Porous Sacroiliac Joint (SIJ) Threaded Implant For Percutaneous Minimally Invasive SI Joint Fusion the patent includes a device claim of our threaded implant with the fusion channel; also an embodiment with a 3D porous structure MALDEN, Mass. (PRWEB) September 18, 2021 Vito Lore, the VP of innovations at KICVentures Group, said "the patent includes a device claim of our threaded implant with the fusion channel; also an embodiment with a 3D porous structure". "Clinically the 3D porous structure is expected to enhance the threaded implant's performance in

New Lab Studies Suggest InBios COVID-19 POC Antigen Detection Test Will Detect Delta Variant

Source Node: https://www.prweb.com/releases/new_lab_studies_suggest_inbios_covid_19_poc_antigen_detection_test_will_detect_delta_variant/prweb18146251.htm
Time Stamp: August 22, 2021 9:00 AM - Modified On: August 22, 2021 - Published By:
Source Cluster:
Republished By Plato

SCoV-2 Ag Detect Rapid Test SEATTLE (PRWEB) August 22, 2021 InBios International Inc., a leading developer of diagnostic tests for emerging infectious diseases, announced today that laboratory studies suggest its SCoV-2 Ag Detect Rapid Test will detect the Delta variant (lineage B.1.617.2), which is responsible for a rapid rise of infections and deaths in the US and around the world. Initial studies suggest that InBios’ point-of-care antigen test will detect the Delta variant at rates similar to the USA-WA1-2020 isolate that was used to develop the assay. “Having a rapid